Continuing the trend of consolidation in the dermatology market, Allergan has agreed to buy SkinMedica’s topical aesthetics skincare business for up to US$375 M. With the acquisition, Allergan will gain a range of physician-dispensed non-prescription and prescription products, including Epiquin® Micro (hydroquinone 4%) for facial discolouring and Vaniqa® (eflornithine hydrochloride) cream 13.9% to reduce the growth of unwanted facial hair in women. The deal does not include the SkinMedica Colorescience aesthetic make-up line, which will be spun-out.